HopSo-LP Tablet 90 mg + 400 mg is a fixed-dose combination antiviral therapy containing Ledipasvir 90 mg and Sofosbuvir 400 mg. This combination is specifically designed for the treatment of chronic hepatitis C virus (HCV) infection.

• Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor that blocks viral replication by inhibiting the HCV RNA polymerase enzyme.

• Ledipasvir is an NS5A inhibitor that prevents viral replication and assembly of new virus particles.

Together, these agents provide potent, synergistic antiviral activity against HCV, making HopSo-LP a cornerstone of modern, interferon-free therapy. The combination is convenient as it allows once-daily oral dosing, improving adherence and clinical outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

HopSo-LP Tablet 90 mg + 400 mg is indicated for:

• Chronic hepatitis C virus (HCV) infection in adults

• Effective against HCV genotypes 1, 4, 5, and 6

• Treatment-naïve and previously treated patients, including those with compensated cirrhosis

• Patients co-infected with HIV, under specialist supervision

• An interferon-free alternative, reducing adverse effects associated with older therapies

Clinical studies demonstrate that this combination achieves high rates of sustained virologic response (SVR), which is considered a cure for hepatitis C.

Dosage and Administration

• Adults: One tablet daily, with or without food, or as prescribed by a healthcare professional

• Duration typically ranges from 12 to 24 weeks, depending on HCV genotype, prior treatment history, and liver status

• May be used alone or with ribavirin in specific cases as per physician guidance

• Do not split, crush, or chew the tablet; swallow it whole with water

• Strict adherence to daily dosing is essential to prevent viral resistance and ensure optimal outcomes

Benefits

• Highly effective against multiple HCV genotypes, achieving cure rates above 95% in many cases

• Dual mechanism of action blocks viral replication at different stages, enhancing efficacy

• Once-daily oral dosing simplifies treatment and improves adherence

• Interferon-free regimen, reducing side effects such as flu-like symptoms, depression, and anemia

• Supports liver function recovery and reduces progression to cirrhosis or liver cancer

• Suitable for both treatment-naïve and experienced patients, including those with compensated liver disease

Side Effects

HopSo-LP Tablet is generally well tolerated. Common side effects may include:

• Fatigue, headache, nausea, and insomnia

• Rarely, mild diarrhea or muscle pain

• When combined with ribavirin, possible anemia or irritability may occur

• Allergic reactions are uncommon but may include rash, itching, or swelling

Any persistent or severe symptoms should be reported to a healthcare provider immediately.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Not recommended in decompensated liver disease without specialist supervision

• Pregnant and breastfeeding women should use only under medical guidance

• Inform the healthcare provider about all concomitant medications, particularly acid-reducing drugs, as they may reduce absorption of Ledipasvir

• Monitor liver function and HCV viral load throughout therapy

• Avoid alcohol and hepatotoxic drugs during treatment for optimal liver recovery

Storage

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.

HopSo-LP Tablet 90 mg + 400 mg (Ledipasvir + Sofosbuvir) is a highly effective, convenient, and safe antiviral therapy for chronic hepatitis C, offering potent viral suppression, improved liver health, and high cure rates under proper medical supervision.